Sanofi and the Institut Pasteur create four prestigious awards

SanofiSanofi (EURONEXT: SAN and NYSE: SNY) and the Institut Pasteur announced the creation of the Sanofi-Institut Pasteur Awards to encourage scientific excellence in the service of health.

Four hundred and eighty thousand euro (480,000 €) will support four innovative research projects demonstrating real progress in the life sciences and providing answers to major healthcare problems, more specifically in four fields: neglected tropical diseases, vaccine innovation, drug resistance, and therapeutic approaches to ageing and regenerative medicine.

The jury is composed of seven prestigious members: Prof. Peter C. Agre, John Hopkins University, Baltimore, United States, Nobel Prize in Chemistry 2003, Prof. Elizabeth H. Blackburn, University of California, San Francisco, Nobel Prize in Medicine 2009, Prof. Pascale Cossart, Head of the Bacteria-Cell Interactions Unit, Institut Pasteur, Prof. Alice Dautry, President of the Institut Pasteur, Prof. Depei Liu, Vice President of the Academy of Engineering of China and President of the Chinese Academy of Medical Sciences and the Peking Union Medical College, Dr Robert Sebbag, Vice President, Access to Medicines, Sanofi, and Dr Elias Zerhouni, President, Global R&D, Sanofi.

"With these awards, the Institut Pasteur confirms its commitment to the greater interest by encouraging research, notably in conditions affecting the most vulnerable populations and diseases sharply on the rise in the world," said Alice Dautry, President of the Institut Pasteur.

"I am enthusiastic about this collaborative endeavour with the Institut Pasteur which will promote and support research teams capable of making a real difference in the lives of patients and in key areas of public health," said Elias Zerhouni, President, Global R&D of Sanofi. "The Sanofi-Institut Pasteur Awards follow a long-standing partnership between our two organizations."

Candidates can submit their applications by April 20, 2012. The prices will be awarded in November 2012 at the Institute Pasteur in Paris. For further information: www.sanofiinstitutpasteur-awards.com

Sanofi and the Institut Pasteur have a long history of partnership which reflects Louis Pasteur philosophy which states that "Pure research and applied research are not separate entities. Research and its applications are united together as the fruit of the tree is united with the branch that bears it."

The first partnership emerged through the establishment of the dedicated fund "Fighting Parasitic Diseases" which led to the creation of new research teams. Today, Sanofi also sponsors the Center for Integrative Biology of Emerging Diseases (BIME) and collaborates with the Institut Pasteur in the development of new vaccines against infectious diseases.

About the Institut Pasteur
An internationally renowned center of biomedical research, the Institut Pasteur, created in 1887 by Louis Pasteur, is a recognized private non-profit foundation. Its mission is to contribute to preventing and fighting disease in France and around the world, through scientific and medical research, education, and public health activities. About 2600 individuals work on its campus in Paris. In addition to research in the field of life sciences, a significant part of its work is dedicated to the study of infectious, genetic and neurodegenerative diseases as well as certain cancers. The Institut Pasteur is at the heart of an international network comprising 32 institutes on 5 continents. Since its creation, 10 researchers have received the Nobel Prize in Medicine.

About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Most Popular Now

Positive Phase 1 data from mRNA-based individualiz…

BioNTech SE (Nasdaq: BNTX, "BioNTech") announced initial data from an ongoing investigator-initiated first-in-human Phase 1 study evaluating the safety and tolerability o...

FDA approves RIABNI™ (rituximab-arrx), a biosimila…

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with ...

Pfizer to invest $120 million to produce COVID-19 …

Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Mic...

Proteomic study of 2,002 tumors identifies 11 pan-…

A new study that analyzed protein levels in 2,002 primary tumors from 14 tissue-based cancer types identified 11 distinct molecular subtypes, providing systematic knowled...

A new technology offers treatment for HIV infectio…

A new study from Tel Aviv University offers a new and unique treatment for AIDS which may be developed into a vaccine or a one time treatment for patients with HIV. The s...

Broadly neutralizing antibodies could provide immu…

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published Ju...

Sanoff offers perspective on a promising rectal ca…

UNC Lineberger Comprehensive Cancer Center's Hanna K. Sanoff, MD, MPH, is the author of a viewpoint in the New England Journal of Medicine that provides a perspective on ...

Boehringer Ingelheim signs option to acquire Truti…

Boehringer Ingelheim announced the signing of an option to acquire Trutino Biosciences Inc. (the "Transaction"), a San Diego-based biotech company. Trutino Biosciences...

Novel drug combo activates natural killer cell imm…

Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, the...

Novartis announces Nature Medicine publication of …

Novartis announced that Nature Medicine published final results from both the two- and three-copy cohorts of the completed Phase 3 SPR1NT trial as separate companion manu...

COVID-19 rebound after taking Paxlovid likely due …

Paxlovid is the leading oral medication for preventing severe cases of COVID-19 in high-risk individuals. However, symptoms returned in some patients after treatment was ...

Biomarkers found that could be drug targets agains…

Biomarkers that could be targets for novel drugs to treat glioblastoma brain tumors have been identified by investigators at Georgetown Lombardi Comprehensive Cancer Cent...